ORKA

Oruka Therapeutics Stock Analysis

AI Rating

Good
  • Quality3/10
  • Growth 5/10
  • Value 6/10
Oruka Therapeutics sales and earnings growth
ORKA Growth
Neutral
  • Revenue Y/Y 0.00%
  • EPS Y/Y 70.65%
  • FCF Y/Y -15.81%
Oruka Therapeutics gross and profit margin trends
ORKA Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y 0.00%
Oruka Therapeutics net debt vs free cash flow
ORKA Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage NA

Oruka Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks